Librela® - Zorbium® The Legal Reality Behind Pet Drug Safety

Understanding the ‘Correlation vs. Causation’ Dismissal – January 2026
The following analysis was shared by a Librela® advocacy group member and is republished here with permission.

While written in response to Librela® cases, the concerns about clinical trial limitations, regulatory oversight, and dismissal of owner-reported adverse events apply equally to Zorbium® and other veterinary pharmaceuticals. Some language has been adapted for clarity while preserving the author’s core arguments.

The “Correlation Doesn’t Equal Causation” Problem

When pet owners report devastating effects following administration of veterinary pharmaceuticals, they’re often met with the dismissive response: “correlation doesn’t equal causation.” This phrase has become veterinary medicine’s go-to defense in explaining away serious adverse events and denying culpability.

While “correlation doesn’t equal causation” is a valid scientific principle, it’s being misapplied to shut down legitimate safety discussions. The real question isn’t whether every individual case proves causation, it’s whether the pattern of reports justifies further investigation and warranted warnings to pet owners.

What Constitutes Valid Scientific Proof
Scientific proofs are derived from trials using multiple verifiable, peer-reviewed, unrelated sources with reproducible results and strict parameters:
Adequate sample size: Testing must include reasonable numbers of subjects across different breeds (including mixed breeds), sexes, ages, and body weights to provide realistic, reproducible results
Sufficient time frames: Test periods must be long enough to capture the complete picture of what can be expected, including delayed adverse effects
Proper controls: The gold standard is randomized controlled trials (RCT) where testing is done on subjects that are “clean” (have no contact with the product) compared to groups receiving the test product
Independent verification: Research must be conducted by third parties unrelated to the manufacturer to avoid conflicts of interest
Peer review: Testing agencies must be reputable facilities that regularly perform and publish research reviewed by expert researchers in their respective fields
Where Veterinary Drug Approval Falls Short
Limited Time Frames: Librela® is a prime example. It has absolutely no long-term history, not even medium-term data. The result has been an increasing number of pets with devastating injuries and deaths clearly documented by owners. Zorbium® similarly lacks adequate long-term safety data.
Manufacturer-Only Testing: One of the most problematic issues is that companies are allowed to present their own research to the FDA as the primary basis for approval. Nowhere else in life does one opinion validate any claim. It’s the classic case of “the fox guarding the henhouse.” Testing should be conducted by third parties unrelated to manufacturers to ensure results aren’t skewed toward desired outcomes that declare products “efficient and safe”—and therefore profitable.
Inadequate Sample Sizes: Librela®’s clinical trials involved only 52 test subjects over just 56 days. This is never acceptable in good scientific testing. Most pet owners plan to have their animals for longer than two months—manufacturers should be required to provide data that reflects real-world, long-term use.
Missing Variables: Comprehensive testing should include varying dosages, application times (before/after meals), and activity levels (sedentary or active animals). Only when these considerations are addressed do we have reliable, validated, and accurate data to confirm efficacy and safety. These factors are rarely adequately reported by manufacturers because longer, more comprehensive testing might reveal adverse effects and reduce revenue for investors and prescribing veterinarians.
Understanding Side Effects vs. Adverse Events
It’s important to distinguish between these two terms:
Side Effects are usually mild in nature and may be beneficial or not. They are typically self-resolving either through discontinuation or with time. Side effects usually appear during clinical trials and are considered “additions” that accompany the intended results of administering a pharmaceutical.
Adverse Events are vastly different—they have absolutely no beneficial effect, are often not expected (being rare or non-existent in trials), and are severe and/or life-threatening. They may result in permanent damage or death.
Understanding this distinction helps explain why sudden death, acute kidney injury, or neurological collapse cannot be dismissed as mere “side effects” of sedation drugs like Zorbium®.
Why Pattern Recognition Matters: The Zorbium® Case
When we see consistent temporal patterns, biological plausibility, and disproportionate outcomes in specific populations, dismissing these as “mere correlation” is scientifically irresponsible. These are exactly the signals that trigger drug safety investigations in human medicine.
For Zorbium® specifically, we’ve documented:
Over 100 adverse event case submissions from pet owners
Cats dying within hours to days of Zorbium® administration
A statistically significant overrepresentation of black cats among reported deaths—a pattern that cannot be explained by population distribution alone
Consistent reports of acute onset adverse events (sudden collapse, respiratory distress, acute kidney injury)
Temporal clustering that strongly suggests drug-related causation
These aren’t isolated correlations, they’re consistent safety signals that demand investigation, not dismissal.
The Regulatory Capture Problem
Adding to these concerns is the documented issue of regulatory capture at the FDA’s Center for Veterinary Medicine. Timothy Schell, former Vice President at Elanco (manufacturer of multiple veterinary pharmaceuticals), now heads the division responsible for overseeing drug safety. This revolving door between pharmaceutical companies and regulatory agencies raises serious questions about whose interests are being protected.
What Pet Owners Deserve
Pet owners deserve the same standard of post-market surveillance and transparent safety reporting that exists (however imperfectly) in human medicine. When veterinarians dismiss owner observations and temporal associations with “correlation doesn’t equal causation,” they’re not practicing good science—they’re avoiding accountability.
The next time someone uses this dismissal, ask them about the validity of the original approval studies: Were they conducted by independent third parties? Did they include adequate sample sizes across diverse populations? Were they long enough to detect delayed adverse events? Was there proper peer review by unrelated experts?
The blank look on their face will likely confirm what you already know—often through devastating personal experience.
Moving Forward
Right now, informed pet owners sharing information is our only defense against inadequately tested pharmaceuticals. Whether it’s Librela®, Zorbium®, or other veterinary drugs rushed to market with limited safety data, we must continue documenting patterns, demanding transparency, and refusing to let legitimate safety concerns be dismissed with thought-terminating clichés.
If you’ve experienced an adverse event with Zorbium® or Librela®, please report it to the FDA and document your case through our submission form. Every report strengthens the safety signal and helps protect other pets.

[End of adapted content]
Original analysis courtesy of a former emergency medical provider (27 years) and dedicated animal advocate from the Librela® advocacy community. Adapted for zorbium.com with permission.

Librela® Class Action Dismissed in NJ: Why Pet Drug Lawsuits Fail

In an unpublished opinion, a federal district court in New Jersey dismissed a class action lawsuit brought by 8 pet owners against Zoetis over allegations that the company misrepresented the safety of Librela® (bedinvetmab injection), a monoclonal antibody treatment for osteoarthritis pain in dogs. This dismissal reveals critical barriers to legal accountability in veterinary pharmaceuticals—barriers that make a Zorbium® lawsuit virtually impossible.

The Librela® Case: Everything Going Right Still Wasn’t Enough

The Librela® plaintiffs had significant advantages:

10,000+ adverse event reports to FDA
FDA investigation and safety alert issued (December 2024)
Required label updates based on post-approval safety data
8 organized plaintiffs with documented harm and veterinary expenses
Similar adverse events across multiple dogs (neurological injuries, death)

Despite all of this, the court dismissed the case.

Why the Court Dismissed the Lawsuit

The court identified fatal flaws in the lawsuit that apply to virtually all pet drug cases:

1. The Learned Intermediary Doctrine The court ruled that drug manufacturers only have a duty to warn veterinarians, not pet owners directly. As long as Zoetis provided warnings to veterinary professionals, they satisfied their legal duty—even if individual pet owners never saw those warnings or weren’t adequately informed by their veterinarians.

2. FDA-Approved Warnings Presumed Adequate Under New Jersey Products Liability Act, FDA-approved warnings are presumed adequate unless plaintiffs can prove the manufacturer deliberately concealed or withheld post-approval risk information. The fact that Zoetis updated the label in 2025 actually worked against the plaintiffs—it showed the company was disclosing newly discovered risks, not hiding them.

3. No Specific Misrepresentation Identified Plaintiffs couldn’t point to specific false statements they personally saw and relied on. Generic claims that they “believed the drug was safe” were deemed too vague. Each plaintiff needed to identify exactly what Zoetis said, where they saw it, and how it influenced their decision.

4. Failed to Prove Design Defect To win on design defect theory, plaintiffs must:

Identify a feasible safer alternative design
Show that alternative would have received FDA approval
Prove the drug’s risks outweigh its benefits

The court found plaintiffs failed on all three elements.

5. Federal Preemption Issues Once FDA approves a drug, federal law prohibits manufacturers from unilaterally changing the formulation. This creates a catch-22: plaintiffs must prove a safer design exists, but manufacturers can’t implement design changes without FDA approval.

Why This Makes a Zorbium® Lawsuit Nearly Impossible

If Librela®—with FDA investigation, safety alerts, and 10,000+ reports—couldn’t survive a motion to dismiss, Zorbium® faces insurmountable obstacles:

Legal Requirement	Librela® (Dismissed)	Zorbium® (No Lawsuit)
FDA Investigation	✓ Completed	✗ None
Safety Communications	✓ Issued	✗ None
Required Label Updates	✓ Mandated	✗ None
Proof of Concealment	✗ Failed	Even less evidence
Organized Plaintiffs	✓ 8 people	✗ None
Court Outcome	DISMISSED	Won’t even file

The Zorbium® Reality:

Elanco provides warnings to veterinarians (learned intermediary satisfied)
FDA approved Zorbium® and its warnings (presumption of adequacy)
No evidence Elanco concealed post-approval data (they report adverse events to FDA as required)
Difficult to prove a “safer alternative” exists for post-surgical pain management
Would need to prove risks outweigh benefits (challenging for a pain medication)
No FDA investigation to point to as evidence of problems

What Actually Survives: Economic Harm, Not Safety Claims

The contrast is stark:

Product Safety Lawsuits → Dismissed

Librela®: 10,000+ adverse events, FDA action → Dismissed
Individual pet deaths → Insufficient damages, can’t prove causation

Economic Harm Lawsuits → Proceed

Elanco’s Advantix® price-fixing case → Survived dismissal (October 2025)
Financial harm to consumers → Sufficient damages
Easier to prove than individual product liability

Elanco’s Financial Pressure

The context matters. As of Q3 2024, Elanco faces significant financial challenges:

Debt-to-equity ratio of 55.8%
Failing multiple financial health criteria
Total debt of $3.88 billion
Under pressure to maintain revenue streams

This financial stress provides context for why Elanco:

Has not voluntarily paused Zorbium® sales despite over 300+ cat deaths
Continues marketing without enhanced warnings beyond what FDA requires
Obtained FDA Emergency Use Authorization for New World Screwworm treatment in November 2025 (for a parasite not present in the U.S.) while Zorbium® remains on market with documented deaths

The priority is clear: FDA fast-tracks approval for hypothetical threats while actual, documented deaths continue without investigation.

The Broken System Revealed

The Librela® dismissal exposes a system with no accountability for veterinary drug safety:

Manufacturers satisfy legal duty by warning veterinarians—pet owners’ lack of knowledge is irrelevant
FDA approval creates presumption of safety—even when thousands of adverse events occur
Legal barriers make lawsuits unwinnable—even with FDA investigation and safety alerts
Individual damages too small—veterinary expenses insufficient to overcome legal hurdles
FDA acts inconsistently—investigates some drugs (Librela® 12.6% fatality) but not others (Zorbium® 9.3% cats, 50% dogs) NOT APPROVED FOR DOGS

What This Means for Zorbium® Victims

The legal dismissal of the Librela® case confirms what we’ve stated from the beginning: there isn’t enough money, nor loss, to warrant a lawyer taking these cases.

Even with:

Thousands of adverse event reports
FDA investigation and safety alerts
Multiple organized plaintiffs
Documented veterinary expenses and harm

…the lawsuit still failed.

Zorbium® has none of these advantages. No FDA investigation. No safety alerts. No organized plaintiffs. No chance of legal success under current law.

This is why documentation, FOIA requests, data analysis, and public awareness remain the only viable paths to accountability. The legal system, as currently structured, cannot provide justice for pets harmed by FDA-approved drugs.

Congressional Action Required

The Librela® dismissal demonstrates that current laws are insufficient to protect animals or provide recourse to pet owners. The combination of:

FDA’s inconsistent enforcement (acts on Librela®, ignores Zorbium®)
Learned intermediary doctrine (manufacturers only warn vets, not owners)
Presumption of adequacy for FDA-approved warnings
Insufficient individual damages to sustain litigation

…creates a system where dangerous drugs remain on the market with no accountability mechanism.

Congress must address:

Why FDA investigates some drugs but not others with comparable or worse safety profiles
Whether the learned intermediary doctrine adequately protects pet owners
How to create meaningful accountability when legal remedies fail
Whether financial pressures on manufacturers influence safety decisions

Sources:

Federal District Court of New Jersey unpublished opinion (Librela® class action dismissal)
Elanco Q3 2024 10-Q filing (SEC)
FDA adverse event database
FDA Dear Veterinarian Letter (December 2024)
DVM360 legal analysis

Last Updated: November 2025

FDA Regulatory

Librela® (bedinvetmab)

Species: Dogs (Approved)

Indication: Osteoarthritis pain control

Approval: May 5, 2023

Manufacturer: Zoetis

12.6% Case Fatality Rate
(458 deaths / 3,674 adverse event reports)

✓ FDA TOOK ACTION
Full investigation & safety alert issued

Zorbium® (buprenorphine)

Species: Cats (Approved for post operative pain) / Dogs (Off-label)

Indication: Post-surgical pain (cats only)

Approval: January 20, 2022

Manufacturer: Elanco

9.3% Cat Case Fatality Rate

50% Dog Case Fatality Rate

✗ FDA NO ACTION
No investigation, no alerts, no response

The Regulatory Crisis

FDA investigated Librela® for a 12.6% case fatality rate but has yet to investigate:

Zorbium® cats: 9.3% case fatality rate in the approved species
Zorbium® dogs: 50% case fatality rate in off-label use

This means Zorbium® is killing cats at nearly the same rate that triggered Librela®’s investigation, and killing dogs at more than double the rate, yet FDA takes action for one but not the other.

FDA Safety Protocol Comparison

Safety Protocol	Librela® (12.6%)	Zorbium® Cats (9.3%)	Zorbium® Dogs (50%)
Statistical Analysis	✓ COMPLETED	✗ NO ACTION	✗ NO ACTION
Case Series Evaluation	✓ COMPLETED	✗ NO ACTION	✗ NO ACTION
Safety Communication	✓ ISSUED	✗ NOT ISSUED	✗ NOT ISSUED
Label Updates	✓ MANDATED	✗ NO ACTION	✗ NO ACTION
Death Disclosure	✓ REQUIRED	✗ NO ACTION	✗ NO ACTION

The Primary Victims: Cats

300+ cats (and dogs, not approved for dogs) have died from the drug specifically designed to help them. These cats received Zorbium® mostly off/extra label and some for its approved indication – post-surgical pain management – yet FDA has not:

Conducted any safety analysis despite 9.3% overall case fatality rate (including 50% fatality rate in dogs)
Issued any safety communications to veterinarians
Required any label updates or death disclosures
Mandated any owner notification requirements

Meanwhile, FDA thoroughly investigated Librela® for a similar 12.6% case fatality rate in dogs.

Two years later Elanco is still telling poor pet parents their reps need to be doing a better job and explaining safety issues. Two years later veterinarians are still telling pet parents that they are unaware of any deaths!

Congressional Action Needed

This regulatory double standard demands immediate congressional oversight. FDA has the tools and authority to investigate veterinary drug safety concerns, yet selectively applies them.

Key Questions for FDA:

If 12.6% case fatality rate triggers investigation for Librela®, why doesn’t 9.3% trigger action for Zorbium® cats.
Why is there no response to 50% case fatality rate in off-label dog use?
What scientific justification exists for these different investigative thresholds?

Official Sources & Documentation

Last Updated: June 2025
Data Sources: FDA adverse event reports, official FDA communications
Note: Case fatality rates represent deaths among reported adverse events